新型冠状病毒感染合并高血糖症患者的研究现状及对高血糖管理策略的探讨  

Current Status of Research on COVID-19 Patients With Concomitant Hyperglycemia and the Management Strategies of Hyperglycemia

作　　者：夏娟 杜丽娟 席学莉 徐筑萍[2] XIA Juan;DU Lijuan;XI Xueli;XU Zhuping(Department of Respiratory and Critical Care Medicine,Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China;Department of Ophthalmology,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]贵州医科大学附属医院呼吸与危重症医学科,贵阳550004 [2]四川大学华西医院眼科,成都610041

出　　处：《四川大学学报（医学版）》2024年第1期230-235,共6页Journal of Sichuan University(Medical Sciences)

基　　金：成都市科技局重点研发支撑计划(No.2021-YF09-00024-SN)资助。

摘　　要：新型冠状病毒感染(coronavirus disease 2019,COVID-19)在全球范围内的大流行严重威胁着人类健康,特别是重型、危重型患者具有较高的死亡率,高血糖症是这类患者不良预后的高危因素。COVID-19患者容易出现高血糖症,无论既往是否患糖尿病。糖皮质激素治疗是COVID-19患者抗炎方案的重要治疗措施,而糖皮质激素的使用显著增加了COVID-19患者高血糖事件的发生,导致不良预后。及时的血糖监测及早期高血糖的干预将有利于COVID-19患者的病情转归。本文就近年来COVID-19患者并发高血糖症的潜在形成机制,以及针对该类患者血糖管理策略的研究进展作全面的综述,以期优化管理COVID-19患者的高血糖状态,改善疾病的转归。The global pandemic of coronavirus disease 2019(COVID-19)poses a serious threat to human health,leading to a relatively high mortality in patients with severe or critical conditions in particular.Hyperglycemia is one of the high-risk factors for poor prognosis in these patients.Patients with COVID-19 are more likely to develop hyperglycemia,regardless of whether there is a previous history of diabetes mellitus.Glucocorticoid therapy is an important part of the anti-inflammatory regimen for COVID-19.However,the use of glucocorticoid significantly increases the occurrence of hyperglycemic events in COVID-19 patients,ultimately leading to poor prognosis.Timely monitoring of blood glucose and early intervention for hyperglycemia contribute to the improvement in the outcome of COVID-19 patients.In this paper,we comprehensively reviewed the potential mechanisms of COVID-19 and concomitant hyperglycemia.We reviewed the latest findings on the blood glucose management strategies for COVID-19 patients with concomitant hyperglycemia,aiming to optimize the management of hyperglycemia in COVID-19 patients and improve the outcome of the disease.

关 键 词：新型冠状病毒感染 糖皮质激素 高血糖症 血糖控制 综述 

分 类 号：R587.1[医药卫生—内分泌] R511[医药卫生—内科学]